Compare TYRA & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | CMRE |
|---|---|---|
| Founded | 2018 | 1974 |
| Country | United States | Monaco |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2021 | 2010 |
| Metric | TYRA | CMRE |
|---|---|---|
| Price | $27.73 | $15.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 1 |
| Target Price | ★ $47.50 | $12.00 |
| AVG Volume (30 Days) | ★ 450.8K | 325.1K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.10% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.82 | $10.84 |
| 52 Week High | $40.65 | $18.06 |
| Indicator | TYRA | CMRE |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 48.08 |
| Support Level | $27.40 | $13.86 |
| Resistance Level | $33.35 | $15.86 |
| Average True Range (ATR) | 1.34 | 0.45 |
| MACD | 0.39 | 0.01 |
| Stochastic Oscillator | 66.51 | 26.17 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.